Alkermes PLC (NASDAQ:ALKS) updated its FY17 earnings guidance on Thursday. The company provided earnings per share guidance of ($0.10) – $0.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.04). The company issued revenue guidance of $850-880 million, compared to the consensus revenue estimate of $893.66 million.
A number of analysts have recently weighed in on the stock. Barclays PLC set a $50.00 target price on shares of Alkermes PLC and gave the stock a hold rating in a research report on Thursday, October 26th. ValuEngine downgraded shares of Alkermes PLC from a hold rating to a sell rating in a research report on Monday, October 23rd. J P Morgan Chase & Co set a $78.00 price objective on shares of Alkermes PLC and gave the company a buy rating in a research report on Friday, October 27th. Citigroup Inc. set a $62.00 price objective on shares of Alkermes PLC and gave the company a hold rating in a research report on Thursday, October 26th. Finally, Jefferies Group LLC set a $69.00 price objective on shares of Alkermes PLC and gave the company a buy rating in a research report on Friday, August 25th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $63.55.
Shares of Alkermes PLC (NASDAQ:ALKS) opened at $47.85 on Friday. Alkermes PLC has a one year low of $46.80 and a one year high of $63.40. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72.
Alkermes PLC (NASDAQ:ALKS) last released its earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.04. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The company had revenue of $217.40 million for the quarter, compared to analysts’ expectations of $231.29 million. During the same quarter last year, the business earned ($0.09) EPS. The firm’s revenue was up 20.6% compared to the same quarter last year. sell-side analysts expect that Alkermes PLC will post -0.59 earnings per share for the current year.
In other Alkermes PLC news, Director Paul J. Mitchell sold 1,500 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $50.77, for a total transaction of $76,155.00. Following the completion of the sale, the director now directly owns 9,500 shares of the company’s stock, valued at approximately $482,315. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP James M. Frates sold 20,932 shares of the stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $47.58, for a total transaction of $995,944.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 102,498 shares of company stock valued at $5,018,010. Insiders own 5.34% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/12/alkermes-plc-alks-releases-fy17-earnings-guidance.html.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.